United States - English - NLM (National Library of Medicine)

aurora pharmaceutical, inc. - sulfadiazine (unii: 0n7609k889) (sulfadiazine - unii:0n7609k889), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfadiazine 333 mg in 1 ml - equisul-sdt is contraindicated in horses with a known allergy to sulfadiazine, sulfonamide class antimicrobials, or trimethoprim.

United States - English - NLM (National Library of Medicine)

neogen corporation - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x), sulfadiazine (unii: 0n7609k889) (sulfadiazine - unii:0n7609k889) - trimethoprim 67 mg in 1 g - uniprim powder for horses is indicated in horses where potent systemic antibacterial action against sensitive organisms is required. uniprim powder for horses is indicated where control of bacterial infections is required during treatment of: uniprim powder for horses is well tolerated by foals. trimethoprim and sulfadiazine should not be used in horses showing marked liver parenchymal damage, blood dyscrasias, or in those with history of sulfonamide sensitivity.

United States - English - NLM (National Library of Medicine)

neogen corporation - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x), sulfadiazine (unii: 0n7609k889) (sulfadiazine - unii:0n7609k889) - uniprim powder for horses is indicated in horses where potent systemic antibacterial action against sensitive organisms is required. uniprim powder for horses is indicated where control of bacterial infections is required during treatment of: uniprim powder for horses is well tolerated by foals. trimethoprim and sulfadiazine should not be used in horses showing marked liver parenchymal damage, blood dyscrasias, or in those with history of sulfonamide sensitivity.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - trimethoprim sulfate (unii: e377mf8eq8) (trimethoprim - unii:an164j8y0x), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - trimethoprim 1 mg in 1 ml - trimethoprim sulfate and polymyxin b sulfate ophthalmic solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: staphylococcus aureus, staphylococcus epidermidis, streptococcus pneumoniae, streptococcus viridans, haemophilus influenza and pseudomonas aeruginosa. * *efficacy for this organism in this organ system was studied in fewer than 10 infections. trimethoprim sulfate and polymyxin b sulfate ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

proficient rx lp - trimethoprim sulfate (unii: e377mf8eq8) (trimethoprim - unii:an164j8y0x), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - trimethoprim 1 mg in 1 ml - trimethoprim sulfate and polymyxin b sulfate ophthalmic solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: staphylococcus aureus, staphylococcus epidermidis, streptococcus pneumoniae, streptococcus viridans, haemophilus influenza and pseudomonas aeruginosa. * *efficacy for this organism in this organ system was studied in fewer than 10 infections. trimethoprim sulfate and polymyxin b sulfate ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - trimethoprim sulfate (unii: e377mf8eq8) (trimethoprim - unii:an164j8y0x), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - trimethoprim 1 mg in 1 ml - trimethoprim sulfate and polymyxin b sulfate ophthalmic solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: staphylococcus aureus, staphylococcus epidermidis, streptococcus pneumoniae, streptococcus viridans, haemophilus influenza and pseudomonas aeruginosa. * *efficacy for this organism in this organ system was studied in fewer than 10 infections. trimethoprim sulfate and polymyxin b sulfate ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals,inc. - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - trimethoprim 100 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of trimethoprim tablets, usp and other antibacterial drugs, trimethoprim tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. for the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: escherichia coli , proteus mirabilis , klebsiella pneumoniae , enterobacter species, and coagulase-negative staphylococcus species, including s. saprophyticus . cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. therapy may be initiated prior to obtaining the results of these tests. trimethoprim is contraindicated in individuals hypersensitive to trimethoprim and in those with documented megaloblastic anemia due to folate deficiency.

United States - English - NLM (National Library of Medicine)

avkare, inc. - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - trimethoprim 100 mg - to reduce the development of drug resistant bacteria and maintain the effectiveness of trimethoprim tablets, usp and other antibacterial drugs, trimethoprim tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. for the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: escherichia coli , proteus mirabilis , klebsiella pneumoniae , enterobacter species, and coagulase-negative staphylococcus species, including s. saprophyticus . cultures and susceptibility tests should be performed to determine the susceptibility of

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - trimethoprim 100 mg - for the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: escherichiacoli, proteus mirabilis, klebsiella pneumoniae, enterobacter species and coagulase-negative staphylococcus species, including s. saprophyticus. cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. therapy may be initiated prior to obtaining the results of these tests. trimethoprim tablets are contraindicated in individuals hypersensitive to trimethoprim and in those with documented megaloblastic anemia due to folate deficiency.

United States - English - NLM (National Library of Medicine)

mayne pharma - trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - trimethoprim 100 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of trimethoprim tablets, usp and other antibacterial drugs, trimethoprim tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. for the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: escherichia coli , proteus mirabilis , klebsiella pneumoniae , enterobacter species, and coagulase-negative staphylococcus species, including s. saprophyticus . cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. therapy may be initiated prior to obtaining the